SCHEMBL716273

SCHEMBL716273

COc1ccccc1-n1cc(C=O)c(C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
GAA P10253 1/20 0.46
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NLRP3 Q96P20 1/20 0.42
ADORA3 P0DMS8 3/20 0.42
ADORA1 P30542 1/20 0.42
MGLL Q99685 1/20 0.41
TLR2 O60603 1/20 0.41
ERN1 O75460 1/20 0.41
TLR1 Q15399 1/20 0.41
TLR6 Q9Y2C9 1/20 0.41
ADORA2A P29274 2/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27834189 0.82 ALDH1A1 (0.46) ALDH1A1GAANPC1MAPTRAB9A
SCHEMBL27834359 0.81 ALDH1A1 (0.45) ALDH1A1GAANPC1MAPTRAB9A
SCHEMBL719885 0.79 ALDH1A1 (0.46) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL717248 0.79 PARP1 (0.41) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL21354421 0.79 NPC1 (0.47) ALDH1A1GAANPC1MAPTRAB9A
SCHEMBL1842088 0.76 PTGS2 (0.35) ALDH1A1NPC1MAPTRAB9AMEN1
SCHEMBL719535 0.74 PTGS2 (0.63) ALDH1A1NPC1MAPTRAB9AMEN1
SCHEMBL11972479 0.74 POLB (0.37) ALDH1A1NPC1MAPTRAB9AMEN1
SCHEMBL721434 0.74 KMT2A (0.47) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL719241 0.73 KDM4E (0.45) ALDH1A1GAANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885GAA 1254/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885GAA 1254/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.